George Morrow
Director/Board Member bei ALIGN TECHNOLOGY, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robert Bradway | M | 61 | 18 Jahre | |
| Gary Lyons | M | 73 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 31 Jahre |
| Kevin Gorman | M | 66 | 32 Jahre | |
| Stephen Sherwin | M | 75 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 25 Jahre |
| C. Larkin | M | 75 | 20 Jahre | |
| William Rastetter | M | 76 | 14 Jahre | |
| Joseph Hogan | M | 66 | 9 Jahre | |
| Kevin Dallas | M | 60 | 6 Jahre | |
| Sreelakshmi Kolli | F | 49 | 21 Jahre | |
| John Morici | M | 57 | 8 Jahre | |
| Bill Wilson | M | - | 28 Jahre | |
| Johanna Mercier | F | 54 | 3 Jahre | |
| Esteban Santos | M | 56 | 17 Jahre | |
| David Reese | M | 61 | 19 Jahre | |
| Chester Koczynski | M | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 Jahre |
| Dan Troy | M | 64 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 Jahre |
| Anne Myong | F | 56 | 5 Jahre | |
| Caroline Litchfield | F | 55 | 34 Jahre | |
| Susan Siegel | F | 63 | 7 Jahre | |
| Joseph Lacob | M | 68 | 27 Jahre | |
| Darin Lippoldt | M | 58 | 10 Jahre | |
| Robert Eckert | M | 69 | 21 Jahre | |
| Andrea Saia | F | 66 | 11 Jahre | |
| Richard Pops | M | 62 | 26 Jahre | |
| Christine Poon | F | 71 | 1 Jahre | |
| Ronald Sugar | M | 75 | 14 Jahre | |
| Leslie Norwalk | F | 58 | 26 Jahre | |
| Shalini Sharp | F | 49 | 4 Jahre | |
| Dimitri Grigoriadis | M | 65 | 31 Jahre | |
| Matthew Busch | M | 50 | 20 Jahre | |
| Simon Beard | M | 57 | 10 Jahre | |
| Matthew Abernethy | M | 44 | 7 Jahre | |
| Zelko Relic | M | 59 | 11 Jahre | |
| Raj Pudipeddi | M | 51 | 3 Jahre | |
| Eiry Roberts | M | 60 | 6 Jahre | |
| Mojdeh Poul | F | 61 | 1 Jahre | |
| Kevin Conroy | M | 58 | 1 Jahre | |
| Julie Ann Coletti | F | - | 6 Jahre | |
| Jude Onyia | M | 60 | 3 Jahre | |
| Ingrid Delaet | M | 58 | 3 Jahre | |
| Karim Boussebaa | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kenneth Frazier | M | 69 | 30 Jahre | |
| Richard Kogan | M | 81 | 21 Jahre | |
| Frank Herringer | M | 81 | 15 Jahre | |
| Roger E. George | M | 58 | 17 Jahre | |
| Vijay Samant | M | 77 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 19 Jahre |
| R. Gordon Douglas | M | 89 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 28 Jahre |
| Eric Loumeau | M | 61 | 3 Jahre | |
| Michael Kelly | M | 67 | 14 Jahre | |
| David W. Beier | M | 75 | 10 Jahre | |
| Marc M. P. de Garidel | M | 66 | 15 Jahre | |
| Thomas Prescott | M | 68 | 19 Jahre | |
| Dennis Fenton | M | 72 | 27 Jahre | |
| David-Alexandre C. Gros | M | 51 | - | |
| Gregory L. Tewalt | M | - | 18 Jahre | |
| Andrew Sklawer | M | 41 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Paul Eisenberg | M | - | 14 Jahre | |
| Kathryn Falberg | F | 63 | 6 Jahre | |
| Pamela Wapnick | F | 58 | 9 Jahre | |
| Robert Alexander Ingram | M | 81 |
Glaxo Wellcome, Inc.
| 2 Jahre |
| Brian H. Dovey | M | 83 | 5 Jahre | |
| Timothy Proctor | M | 74 |
Glaxo Wellcome, Inc.
| 6 Jahre |
| Deirdre Connelly | F | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 3 Jahre |
| Steven A. Burd | M | 74 | 21 Jahre | |
| H. Watkins | M | 71 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 Jahre |
| Joseph A. Mollica | M | 83 | 20 Jahre | |
| Keith D. Hall | M | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 15 Jahre |
| Thomas Zindrick | M | 65 | 8 Jahre | |
| David McAvoy | M | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Alan R. Engbring | M | - |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 Jahre |
| Mammen P. Mammen | M | 60 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Craig Shepherd | M | - | 7 Jahre | |
| Andreas Grauer | M | 63 | - | |
| Randal Golden | M | 63 | 5 Jahre | |
| Anthony Alan Ramos | M | 57 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 14 Jahre |
| Robert Brown | M | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Diana McKenzie | F | 59 | 12 Jahre | |
| John Moriarty | M | 56 | 6 Jahre | |
| Sean B. W. Martin | M | 61 | - | |
| Jill Broadfoot | F | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 9 Jahre |
| Patricia Cary Sueltz | F | 71 | 2 Jahre | |
| Cynthia Flowers | F | 64 | 5 Jahre | |
| David J. Scott | M | 71 | - | |
| Kelsey Wirth | F | - | 9 Jahre | |
| Gregory Santora | M | 72 | 20 Jahre | |
| David E. Collins | M | 89 | 11 Jahre | |
| Vance D. Coffman | M | 79 | 9 Jahre | |
| Robert C. Merton | M | 79 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 Jahre |
| John McKearn | M | 70 | 5 Jahre | |
| Theodore Schroeder | M | 69 | 8 Jahre | |
| Leonard Hedge | M | 54 | 14 Jahre | |
| Peter Bisgaard | M | 50 | 5 Jahre | |
| David Savello | M | 78 |
Glaxo Wellcome, Inc.
| 12 Jahre |
| Larry Smith | M | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 16 Jahre |
| Gregory Norden | M | 66 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 1 Jahre |
| Iain Dukes | M | 65 |
Glaxo Wellcome, Inc.
| 13 Jahre |
| Reginald Hardy | M | 64 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| François de Carbonnel | M | 78 | 10 Jahre | |
| Bob H. Campbell | M | 86 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 10 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 99 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- George Morrow
- Persönliches Netzwerk
